- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03374085
Recruitment Status Recruiting
First Posted December 15, 2017
Last update posted May 7, 2020
This is an open-label, multi-center, international, Phase 1 study to assess the safety, PK/PD and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with RRMM. RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.
|Experimental: Administration of CC-92480 and Dexamethasone
Escalating doses of CC-92480 in combination with a fixed dose of dexamethasone administered according to two different dosing schedules
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
1. Subject is ≥ 18 years of age and ECOG performance status score of 0, 1 or 2
2. All subjects must have:
1. received at least 3 prior anti-myeloma regimens including at least 2 consecutive
cycles of lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid
and a CD38 antibody (note: induction with or without bone marrow transplant and
with or without maintenance therapy is considered one regimen),
2. documented disease progression on or within 60 days from the last dose of their
last myeloma therapy,
3. in addition to criteria above (a and b), subjects enrolled in Part 2 must have
disease refractory to an immunomodulatory agent (lenalidomide and/or
pomalidomide), a glucocorticoid, a proteasome inhibitor, and a CD38 antibody.
Refractory is defined as disease that is nonresponsive on therapy (failure to
achieve minimal response or development of progressive disease), or progresses
within 60 days of last dose.
3. Subjects must have adequate bone marrow, renal, liver, and cardiac function.
4. Females of childbearing potential (FCBP) and male subjects must agree with the
pregnancy prevention plan.
1. Subject has a significant medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from participating in the study.
2. Subject has non- or oligosecretory multiple myeloma.
3. Subject is unable or unwilling to undergo protocol required venous thromboembolism
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 firstname.lastname@example.org
United States, California
City of Hope Cancer Center
United States, Colorado
Colorado Blood Cancer Institute
United States, Georgia
United States, Massachusetts
Dana Farber Cancer Institute
United States, New York
Memorial Sloan Kettering Cancer Center
United States, Tennessee
Sarah Cannon Cancer Center
United States, Texas
MD Anderson Cancer Center The University of Texas
Tom Baker Cancer Center
Princess Margaret Cancer Centre
Rigshospitalet University Hospital
Helsinki University Hospital
Hospital Universitari Germans Trias i Pujol Can Ruti
Hospital 12 de Octobre
Clínica Universidad de Navarra
Hospital Universitario de Salamanca
University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing
Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine
The Royal Marsden NHS Foundation Trust
Study Director: Tsvetan Biyukov, MD Celgene